Elate

Quick links to important sections

Elate

Method of action: Psychoanaleptics

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Elate

Elate is a trade name used for medicines containing either the antidepressant Dosulepin or the antihistamine Levocetirizine.

Property Description
Active Ingredient Dosulepin OR Levocetirizine
Primary Form Tablet (for Dosulepin) OR Syrup (for Levocetirizine)
Pharmacological Class Tricyclic Antidepressant (TCA) OR H1-Antihistamine (Second-Generation)
General Purpose Mood stabilization/Anxiety (TCA) OR Allergy symptom relief (Antihistamine)
Origin Small Molecule (Synthetic)

What is Elate? Core Identity and Type

Elate refers to two fundamentally different medications, making it essential to identify the active ingredient and its pharmacological class listed on the package. If the active ingredient is Dosulepin (formerly Dothiepin), it is a Tricyclic Antidepressant (TCA), a recognized class of older antidepressant therapies. If it is Levocetirizine, it is a modern selective H1-Antihistamine (Second-Generation). The use of the name Elate for two disparate pharmacological classes is a key differentiating factor specific to this trade name's marketing across various regions.


Composition, Form, and Origin

Both active ingredients in Elate are classified as Small Molecule drugs, confirming they are chemically manufactured, synthetic organic compounds. These medicines are designed for the oral route, with Dosulepin typically found in a tablet form and Levocetirizine often available as an easily swallowed oral syrup. The syrup form positions the Levocetirizine formulation of Elate specifically for patient groups, such as children, who may have difficulty swallowing solid tablets. Levocetirizine is an effective and safe agent for symptom relief in persistent allergic rhinitis.


General Purpose: What Elate Is Used For

The overall therapeutic purpose is entirely dependent on the active ingredient. The function of the TCA (Dosulepin) is clinically recognized to modulate certain brain chemicals called neurotransmitters, helping to restore chemical balance linked to mood disorders. The function of the Antihistamine (Levocetirizine) is to act as a receptor antagonist that prevents the binding of histamine, providing the general benefit of symptomatic relief from general allergy symptoms such as persistent itching or a runny nose.

Regulatory References

  1. Antihistamines Overview (NHS)

What side effects are possible with Elate?

The official safety profile and documented adverse reactions for the medication marketed as Elate are entirely dependent on whether the active ingredient is Dosulepin (a Tricyclic Antidepressant) or Levocetirizine (a Second-Generation Antihistamine).

Adverse Reaction Scope

Feature Dosulepin (TCA) Profile Levocetirizine (Antihistamine) Profile
Common Reactions Drowsiness, dry mouth, blurred vision, constipation, tremor, and postural hypotension (fall in blood pressure upon standing). Somnolence (sleepiness), fatigue, dry mouth, and nasopharyngitis (sore throat/runny nose).
System-Organ Classes Primarily Cardiac, Nervous System, Gastrointestinal, and Ophthalmic systems. Primarily Nervous System, Gastrointestinal, and Immune System.
Serious Reactions Officially documented risks include cardiac arrhythmias, conduction disorders, and suicidal ideation/behaviour reported during therapy or early after discontinuation. Officially documented serious post-marketing reactions include anaphylaxis and angioedema (severe allergic swelling).
Safety Constraints Contraindicated in conditions like recent myocardial infarction or heart block. Use is generally not recommended in patients under 18. Use is contraindicated in patients with end-stage renal disease. Caution is advised regarding the risk of urinary retention.
Exposure Patterns Certain effects like drowsiness are common early in treatment and typically lessen. Risk of suicide may increase in the early stages of recovery. Pruritus (itching) has been reported upon abrupt cessation, usually following long-term use.

Regulatory Safety Summary

Official labeling uses a frequency framework to classify adverse reactions, separating those that are common from those that are rare and potentially more serious. These classifications determine the official risk characteristics of the medicine. Due to the risk of somnolence, official safety notes advise caution when combining either formulation with alcohol or other CNS depressants.

Overdose and Emergency Response

Because Elate contains either Dosulepin (a Tricyclic Antidepressant) or Levocetirizine (an H1-Antihistamine), the overdose profile and required emergency action depend entirely on the active ingredient. Immediate medical attention is required for any suspected overdose of either medication.

Attribute Dosulepin (TCA) Levocetirizine (Antihistamine)
Documented Manifestations Drowsiness, confusion, seizures, hyponatraemia, and ECG changes. Drowsiness (somnolence) in adults; agitation and restlessness in children.
Severe Outcomes High mortality risk due to cardiac arrhythmias (ventricular fibrillation) and circulatory collapse. Low margin of safety. Primarily CNS depression; no specific antidote is known.
Emergency Action IMMEDIATE MEDICAL ATTENTION is mandated. Toxicity onset occurs within 4–6 hours. Seek immediate medical attention for symptomatic and supportive treatment.
Population Notes Increased cardiovascular toxicity risk, particularly in the elderly. Toxicity risk is increased in patients with impaired renal function.

Management for both is symptomatic and supportive. For Dosulepin, regulatory documents underscore the severe cardiotoxicity and high mortality, requiring close supervision. For Levocetirizine, the regulatory profile highlights CNS effects and notes that dialysis is ineffective in removing the drug. The regulatory mandate to seek immediate medical attention reflects the potential for severe, life-threatening outcomes, especially with Dosulepin.

Therapeutic Uses of Elate

What Elate Treats: Main Uses and Benefits

The primary utility of the medication marketed as Elate depends entirely on its active ingredient, providing supportive symptomatic relief across two highly distinct clinical domains: managing symptoms of mood disorders and allergy management. The allergy formulation is relevant for easing symptoms associated with allergic rhinitis and uncomplicated hives (chronic idiopathic urticaria). The Dosulepin formulation is applied in contexts where additional symptomatic support is needed for managing symptoms of depressive illness and Generalized Anxiety.

Therapeutic Support and Symptom Management

Indication domains covered include depression and anxiety for the Dosulepin formulation, and seasonal/perennial rhinitis and chronic urticaria for the Levocetirizine formulation. These uses are relevant when supportive symptom management is appropriate, applied during phases of increased distress or discomfort. The goal is to provide supportive relief when symptoms interfere with routine activities.

“This medication is applied in scenarios where additional management of discomfort is required; it provides support that helps ease the overall symptom burden.”

Symptom Domains Addressed
For Dosulepin: Helps address symptoms related to heightened neurological or muscular activity and inner tension.
For Levocetirizine: Helps manage symptoms related to irritative states and heightened physiological activity.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Elate — Official Regulatory Information

The regulatory eligibility profile for the trade name Elate is strictly defined by its active ingredient: Dosulepin (a Tricyclic Antidepressant) or Levocetirizine (an H1-Antihistamine).


Eligibility Domain Dosulepin (TCA) Official Status Levocetirizine (Antihistamine) Official Status
Contraindications (Must Not Use) Recent myocardial infarction, severe hepatic impairment, cardiac arrhythmias, mania, concurrent MAOI use. End-stage renal disease (creatinine clearance < 10 mL/min), hypersensitivity to cetirizine, or any ingredient.
Age Restrictions Adults are the approved group. Not recommended for children/adolescents (< 18 years). Approved for adults and children ge 6 months. Not established in infants < 6 months.
Physiological Status Pregnancy/Lactation is not recommended or only if essential. Use restricted with conditions like narrow-angle glaucoma. Pregnancy is only if clearly needed. Lactation is not recommended. Conditional use applies to moderate renal impairment in adults.

Connection to the overall eligibility profile: Official regulatory documents establish who is explicitly excluded from using the medicine (contraindications) and which groups are subject to conditional use based on specific physiological or comorbidity criteria. The profile relies exclusively on these official government classifications to structure eligibility, without providing clinical advice or interpretation.

What should I know about interactions with other medicines?

The official interaction profile for Elate is strictly defined by the active ingredient: Dosulepin (TCA) or Levocetirizine (Antihistamine). All interaction statements reflect documented regulatory constraints from government sources (e.g., FDA, EMA, Medsafe).

Official Interaction Classifications

Active Ingredient Interaction Type Restriction or Classification
Dosulepin Monoamine Oxidase Inhibitors (MAOIs) Contraindicated: Co-administration is prohibited due to risk of potentially lethal interaction (Serotonin Syndrome).
Levocetirizine Ritonavir Exposure Modification: Increases Levocetirizine exposure (AUC) by 42% and reduces clearance.
Dosulepin & Levocetirizine Alcohol / CNS Depressants Pharmacodynamic: Avoid concurrent use; leads to additional reduction in alertness and CNS impairment.

Documented Exposure and Clearance Changes

For Dosulepin, its plasma concentration may be elevated by Cimetidine and Strong CYP2D6 Inhibitors, while Carbamazepine may decrease its levels. For Levocetirizine, Theophylline (low-dose) is officially noted to cause a small decrease in clearance. Dosulepin may also antagonize the antihypertensive effect of Adrenergic Neuron Blocking Drugs.

Timing and Population Notes

A 14-day mandatory separation period is required when switching Dosulepin to or from an MAOI. Additionally, Renal or Hepatic Impairment for Dosulepin and Renal Impairment for Levocetirizine are officially noted as conditions where reduced clearance increases the risk and clinical significance of documented interactions.

Mechanism of Action

Modulating Key Neurotransmitter Pathways

Elate's primary action involves acting on specific neurotransmitter pathways in the brain. It functions by inhibiting the reuptake of the chemical messengers Serotonin and Noradrenaline (NE), thereby increasing their concentration within the synaptic cleft. This targeted interference functions to modulate activity within overactive or dysregulated signaling cascades associated with core regulatory systems.


Regulating Systemic Neural Activity

The mechanism extends beyond reuptake to engage multiple receptor systems (e.g., Histamine and Cholinergic receptors), initiating a broader mechanistic cascade. This dual action influences signaling dynamics within both central and peripheral pathways, influencing pathways that regulate physiological responses by acting to dampen excessive neural activity.


Shaping System-Wide Physiological Adjustment

By altering the levels of key mediators and adjusting the activity of multiple receptor domains, Elate is associated with a more regulated state within targeted pathways. This mechanism is associated with altering the activity of overactive physiological responses and reducing the downstream influence of dysregulated signaling, resulting in measurable adjustments to targeted physiological systems that define the drug's mechanism of action.

Dosage and Administration Information

How to Use Elate

The usage instructions for the medication branded as Elate are strictly differentiated by its active ingredient, which may be the antidepressant Dosulepin or the antihistamine Levocetirizine. General administration guidelines define the correct route, dosing schedules, and population-specific adjustments for each.


Official Administration Guidelines

Instruction Category Dosulepin (Tricyclic Antidepressant) Levocetirizine (H1-Antihistamine)
Route of Administration Oral (via tablets or capsules) Oral (via film-coated tablets or oral solution)
Standard Dosing Schedule Initial: 75 mg daily; Maximum: up to 225 mg daily (in specific settings). Standard: 5 mg once daily; Maximum: 5 mg per day.
Timing and Frequency Once daily, often administered as a single dose at night or in divided doses. Once daily, typically administered in the evening, and can be taken without regard to food.
Population Adjustments Older Adults: Lower initial daily dose (50 mg to 75 mg). Pediatric: Not generally recommended under 13 years. Renal Impairment: Dosing frequency must be extended based on kidney function. Pediatric (6 months - 11 years): Specific lower doses apply.

Procedural Usage Protocol

Dosulepin is administered orally, with prescriptions often limited to the smallest quantity consistent with management. The protocol for ending treatment mandates a gradual dose reduction (tapering) over several weeks to withdraw the medication.

Levocetirizine is administered orally once daily in the evening, with the oral solution requiring accurate measurement for dosing. The administration protocol is defined by the need to adjust the dose interval in the presence of reduced kidney function. These instructions collectively define the standardized approach for the initiation, maintenance, and cessation of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Elate

Elate is a trade name that refers to one of two different active ingredients, Levocetirizine (an antihistamine) or Dosulepin (an older antidepressant). Therefore, the available research is entirely separate and must be considered by its active ingredient.


Evidence for Levocetirizine in Allergic Rhinitis and Chronic Urticaria

Research exploring Levocetirizine's use in individuals with allergic rhinitis (seasonal and perennial) includes Randomized Controlled Trials (RCTs). Studies monitored patient-reported outcomes describing perceived discomfort and scores used in research to capture symptoms like sneezing, runny nose, and itching. Researchers also looked at how these outcomes reflecting daily functioning or activity level were captured. Findings describe patterns observed in the studies related to measurements on symptom scales across acute and sustained treatment periods.

For chronic urticaria (hives), the evidence includes short-term RCTs that monitored outcomes linked to inflammatory or irritative states, such as measuring changes in the severity of itching (pruritus) and the number and size of the wheals. Follow-up durations were limited for many of these trials, and long-term effects are not fully established beyond the initial weeks of treatment.

Evidence for Dosulepin in Depressive Illness

Dosulepin was studied for conditions characterized by fluctuating or episodic manifestations, such as major depressive disorder. Studies primarily consisted of older RCTs and meta-analyses comparing Dosulepin with a placebo or with other tricyclic antidepressants. Research examined outcomes related to systemic or functional imbalance by measuring changes on established tools like the Hamilton Depression Rating Scale, focusing on depressive symptom intensity and associated symptoms like anxiety and sleep disruption.

A significant limitation is that the key efficacy evidence is older, and there is a scarcity of modern RCTs directly comparing Dosulepin to the most commonly prescribed current antidepressant classes. Data for certain groups, such as those with complex or multiple health conditions, remain insufficient within the context of Dosulepin-specific trials.

Key Studies & References

  1. Antidepressant prescribing patterns and adverse events following introduction of a National Prescribing Indicator to monitor dosulepin (Used for context on clinical practice change/evidence age)

Frequently Asked Questions (FAQ)

Common questions about Elate (FAQ)

Q: Does Elate start working right away, or does it take time?

A: The expected time frame for noticing effects depends on the active ingredient. For the Dosulepin formulation, which is an antidepressant, official information suggests that changes in mood or symptoms may become noticeable after two to four weeks of use. Levocetirizine is an antihistamine, and relief of allergy symptoms can often be observed relatively quickly.

Q: How soon can I expect to see the full effect of Elate?

A: According to regulatory information, Dosulepin may take a few weeks to reach its full therapeutic effect, with a timeframe of two to four weeks often cited. For Levocetirizine, the relief of allergy symptoms can become apparent consistent with its classification as an antihistamine.

Q: What happens if I stop taking Elate suddenly?

A: Abruptly stopping the Dosulepin formulation is generally not advised and may lead to discontinuation symptoms, which can include anxiety or flu-like symptoms. For the Levocetirizine formulation, stopping after long-term use has been associated with post-marketing reports of severe itching (pruritus). Official documentation stresses that any change in the use of this medication is a medical decision.

Q: Can Elate be used while breastfeeding?

A: Official information indicates that both Dosulepin and Levocetirizine pass into breast milk. Caution is advised, as Levocetirizine may cause drowsiness in the infant or potentially affect milk supply, especially with higher or prolonged doses. Review by a healthcare professional is standard practice regarding the use of either ingredient during lactation.

Q: Is Elate a medication that creates dependence?

A: Neither Dosulepin nor Levocetirizine is generally classified as a habit-forming or controlled substance in regulatory documents. However, for Dosulepin, a gradual dose reduction is the official protocol for cessation to manage the risk of physical discontinuation symptoms.

Q: Can Elate be split or crushed before using?

A: Generally, solid forms of medicine, such as tablets for both active ingredients, are intended to be swallowed whole unless explicitly directed otherwise. While certain low-dose Levocetirizine tablets may be scored for splitting under professional direction, consultation with the prescriber ensures the correct administration procedure is followed for any tablet splitting.

Q: Is it necessary to inform other doctors that I am using Elate?

A: Due to the existence of numerous severe drug-drug interactions and contraindications documented in the official label, regulatory guidelines emphasize the importance of disclosing Elate use to all healthcare providers involved in patient care.

Q: Can Elate cause weight gain or weight loss?

A: Weight gain, or an increase in weight, is documented as an adverse reaction in the regulatory adverse event lists for both the Dosulepin and Levocetirizine formulations.

Q: What if I forget a time to use Elate?

A: Official guidance for a missed dose is typically to take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped; official documentation states that doses must not be doubled to compensate for a missed dose.

Q: Why do some people say they felt worse when they started taking Elate?

A: For the Dosulepin formulation, which is an antidepressant, the official label includes a warning that the risk of suicidal ideation or behavior might be elevated in the early stages of treatment. Separately, common side effects of Levocetirizine, like sleepiness, are also typically observed when first starting the medicine.

Q: What is the information available about Elate and use during pregnancy?

A: Official regulatory documents advise using both Dosulepin and Levocetirizine during pregnancy only if clearly needed. This conditional use classification means that the benefit to the mother is considered against the potential risk to the fetus.

Q: Does Elate affect blood pressure?

A: Yes, Dosulepin is officially associated with a risk of postural hypotension, which is a drop in blood pressure when a person stands up quickly. Levocetirizine has also been associated with reports of general hypotension (low blood pressure) as a side effect.

Q: Does the time of day matter when Elate is used?

A: Official administration guidelines typically specify that the dose is taken once daily in the evening or at night. This specific timing is often advised due to the potential for somnolence (drowsiness) caused by both active ingredients.

Q: What should I do if a side effect doesn't go away?

A: Official guidance uniformly states that if any side effect is bothersome, persistent, or causes concern, the patient should contact their prescribing healthcare professional. This is the necessary step for evaluating symptoms that require attention.

Q: Is it true that Elate can change a person's mood?

A: The active ingredient Dosulepin is a Tricyclic Antidepressant, and its intended mechanism involves modulating neurotransmitter pathways linked to mood disorders. Levocetirizine is an antihistamine and is not indicated for mood-related conditions.

Q: Can Elate affect a person's ability to drive?

A: Both active ingredients carry official warnings regarding the risk of somnolence (drowsiness) and dizziness. Due to this risk, the official product information notes the need for caution regarding activities that require complete mental alertness, such as driving or operating machinery.

Q: Is it normal to have a slight headache when starting Elate?

A: Headache has been reported as an adverse reaction for both the Dosulepin and Levocetirizine formulations and is included in regulatory lists of side effects.

Q: Is there a generic version of Elate available?

A: Yes, the active ingredients in Elate, Dosulepin and Levocetirizine, are both available in many regions as generic formulations under their non-proprietary chemical names.

Q: Does Elate expire quickly after opening the bottle?

A: The Levocetirizine oral solution formulation has a specific instruction in official documents to be discarded four months after the first opening. The Dosulepin tablet formulation typically does not have a documented post-opening limit.

Q: What are the official guidelines regarding maximum use duration for Elate?

A: The duration of use is determined by the specific condition being addressed and the active ingredient. Dosulepin may be prescribed for long-term maintenance, while Levocetirizine is commonly used for short-term allergy relief, although it can be used longer under professional direction.

Q: Are there any known interactions between Elate and birth control pills?

A: Official documents note that Dosulepin may interact with estrogen-containing contraceptives. This interaction could potentially decrease the antidepressant effect of Dosulepin, and this risk is noted for prescriber consideration.

How should Elate be stored and disposed of?

The official storage and disposal requirements for Elate depend on its active ingredient (Dosulepin or Levocetirizine) as defined in regulatory documents.

Requirement Dosulepin (Tablets) Levocetirizine (Oral Solution)
Temperature Store below 25°C Store at 20°C to 25°C (Controlled Room Temperature)
Protection Protect from light and store in original container Do not freeze and keep the container tightly closed
Stability No post-opening limit documented Discard 4 months after first opening

All forms must be kept out of the sight and reach of children. Unused or expired medication must be disposed of in accordance with local regulations and must not be disposed of via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Elate found in:

A-Z Index: